No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis.
Dimethyl fumarate (DMF)
Disease-modifying therapy (DMT)
Functional connectivity
Multiple sclerosis (MS)
Resting-state functional MRI
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
23
10
2021
accepted:
19
01
2022
pubmed:
5
2
2022
medline:
5
2
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
Despite the increased availability of disease-modifying therapies (DMTs) for treating relapsing-remitting multiple sclerosis (RR-MS), only a few studies have evaluated DMT-associated brain functional changes. We investigated whether significant resting-state functional connectivity (FC) changes occurred in RR-MS patients after 6 and 12 months of dimethyl fumarate (DMF) treatment using both a seed-based and data-driven approach. Thirty patients were followed up after 6 months of therapy, and 27 of them reached a 12-month follow-up. Three patients at baseline and only one after 12 months showed gadolinium-enhancing lesions. We did not find any significant FC changes after therapy at either time point. After 12 months of DMF, we observed relatively modest brain volume loss and a significant improvement in Paced Auditory Serial Addition Test 3 s and 25-Foot Walk Test scores. The absence of FC changes could be due to the low degree of baseline inflammation in our patients, though we cannot exclude that more time may be required to observe such changes. No FC changes may reflect a beneficial effect of DMF therapy, as supported by conventional MRI findings and clinical improvement.
Identifiants
pubmed: 35119678
doi: 10.1007/s40120-022-00328-w
pii: 10.1007/s40120-022-00328-w
pmc: PMC8857342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
471-479Informations de copyright
© 2022. The Author(s).
Références
Rocca MA, Preziosa P, Filippi M. Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. Expert Rev Neurother. 2019;19:835–66.
doi: 10.1080/14737175.2019.1555038
pubmed: 30500303
Petsas N, De Giglio L, González-Quintanilla V, Giuliani M, De Angelis F, Tona F, et al. Functional connectivity changes after initial treatment with fingolimod in multiple sclerosis. Front Neurol. 2019;10:153.
doi: 10.3389/fneur.2019.00153
pubmed: 30967828
pmcid: 6438876
Piervincenzi C, Petsas N, De Giglio L, Carmellini M, Giannì C, Tommasin S, et al. Increased within-network functional connectivity may predict NEDA status in fingolimod-treated MS patients. Front Neurol. 2021;12:632917.
doi: 10.3389/fneur.2021.632917
pubmed: 33746887
pmcid: 7973271
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329–33.
doi: 10.1016/j.msard.2015.04.006
pubmed: 26195051
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.
doi: 10.1056/NEJMoa1114287
pubmed: 22992073
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.
doi: 10.1056/NEJMoa1206328
pubmed: 22992072
Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep. 2013;13:394.
doi: 10.1007/s11910-013-0394-8
pubmed: 24061646
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59:344–52.
doi: 10.1002/ana.20740
pubmed: 16437558
Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci. 2005;360:1001–13.
doi: 10.1098/rstb.2005.1634
pubmed: 16087444
pmcid: 1854918
Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209–14.
doi: 10.1073/pnas.0811879106
pubmed: 19357304
pmcid: 2678478
Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, et al. Correspondence of the brain’s functional architecture during activation and rest. Proc Natl Acad Sci U S A. 2009;106:13040–5.
doi: 10.1073/pnas.0905267106
pubmed: 19620724
pmcid: 2722273
Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106:1125–65.
doi: 10.1152/jn.00338.2011
pubmed: 21653723
Worsley KJ. Statistical analysis of activation images [Internet]. Oxford University Press; 2000. https://oxford.universitypressscholarship.com/view/10.1093/acprof:oso/9780192630711.001.0001/acprof-9780192630711-chapter-14 .
Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15:1–25.
doi: 10.1002/hbm.1058
pubmed: 11747097
Smith S, Nichols T. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83–98.
doi: 10.1016/j.neuroimage.2008.03.061
pubmed: 18501637
Duncan NW, Wiebking C, Northoff G. Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—a review of multimodal imaging studies. Neurosci Biobehav Rev. 2014;47:36–52.
doi: 10.1016/j.neubiorev.2014.07.016
pubmed: 25066091
Kelley AE, Andrzejewski ME, Baldwin AE, Hernandez PJ, Pratt WE. Glutamate-mediated plasticity in corticostriatal networks: role in adaptive motor learning. Ann N Y Acad Sci. 2003;1003:159–68.
doi: 10.1196/annals.1300.061
pubmed: 14684443
Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128:1016–25.
doi: 10.1093/brain/awh467
pubmed: 15758036
Colasanti A, Guo Q, Giannetti P, Wall MB, Newbould RD, Bishop C, et al. Hippocampal neuroinflammation, functional connectivity, and depressive symptoms in multiple sclerosis. Biol Psychiatry. 2016;80:62–72.
doi: 10.1016/j.biopsych.2015.11.022
pubmed: 26809249
pmcid: 4918731
Stampanoni Bassi M, Gilio L, Buttari F, Maffei P, Marfia GA, Restivo DA, et al. Remodeling functional connectivity in multiple sclerosis: a challenging therapeutic approach. Front Neurosci. 2017;11:710.
doi: 10.3389/fnins.2017.00710
pubmed: 29321723
pmcid: 5733539
Tomassini V, d’Ambrosio A, Petsas N, Wise RG, Sbardella E, Allen M, et al. The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence: inflammation and brain plasticity in MS. Hum Brain Mapp. 2016;37:2431–45.
doi: 10.1002/hbm.23184
pubmed: 26991559
pmcid: 5069650
Bhattacharyya PK, Lowe MJ, Sakaie KE, Li H, Lin J, Fox RJ. Changes in structural and functional connectivity during two years of fingolimod therapy for multiple sclerosis. Magn Reson Imaging. 2020;74:113–20.
doi: 10.1016/j.mri.2020.09.015
pubmed: 32956806
Stefano ND, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868–76.
doi: 10.1212/WNL.0b013e3181e24136
pubmed: 20530323
De Stefano N, Airas L, Grigoriadis N, Mattle HP, O’Riordan J, Oreja-Guevara C, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28:147–56.
doi: 10.1007/s40263-014-0140-z
pubmed: 24446248
Dupuy SL, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Neurol Ther. 2016;5:215–29.
doi: 10.1007/s40120-016-0054-4
pubmed: 27744504
pmcid: 5130921
Amato MP, Portaccio E, Goretti B, Zipoli V, Iudice A, Della Pina D, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler. 2010;16:1474–82.
doi: 10.1177/1352458510380089
pubmed: 20729256
Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6:286–90.
pubmed: 10962550
Rocca MA, Valsasina P, Martinelli V, Misci P, Falini A, Comi G, et al. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology. 2012;79:1449–57.
doi: 10.1212/WNL.0b013e31826d5f10
pubmed: 22955126
Poutiainen P, Jaronen M, Quintana FJ, Brownell A-L. Precision medicine in multiple sclerosis: future of PET imaging of inflammation and reactive astrocytes. Front Mol Neurosci. 2016;9:85.
doi: 10.3389/fnmol.2016.00085
pubmed: 27695400
pmcid: 5023680
Herranz E, Giannì C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016;80:776–90.
doi: 10.1002/ana.24791
pubmed: 27686563
pmcid: 5115951